Marksans Pharma Limited announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution. The authorization was granted by the UK Medicines & Healthcare Products Regulatory Agency.